Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Seeking Input On Consensus Standard Recognition Draft Policy

This article was originally published in The Gray Sheet

Executive Summary

Priority review of recognized medical device consensus standards by Canada's Therapeutic Products Programme (TPP) will be given to those addressing issues germane to several types of devices, according to the draft Policy on Recognition and Use of Standards under Canada's Medical Devices Regulation.

You may also be interested in...



Canada's Final User-Fee Schedule To Include Three Fee-Reduction Provisions

Final user-fee regulations aimed at recouping the cost of implementing and maintaining Canada's revised medical device regulatory framework are tentatively scheduled for publication in June in the Canada Gazette Part II pending final approval by the Canadian Health Ministry and Treasury Board.

CANADIAN 4-TIER RISK-BASED DEVICE CLASSIFICATION SYSTEM

CANADIAN 4-TIER RISK-BASED DEVICE CLASSIFICATION SYSTEM under development by the Canadian Medical Devices Bureau, according to bureau staffers. The system would divide medical devices into two groups -- one for in vitro diagnostics and another for all other medical devices -- and would establish four levels of regulatory oversight based on risk assessment for each category.

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel